23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
23andMe Holding Co. (ME)
Company Research
Source: Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago. 23andMe will present clinical data, including preliminary efficacy and exploratory biomarker analyses, for the neuroendocrine and ovarian cancer patient cohorts in the Phase 2a portion of its ongoing Phase 1/2a clinical trial. 23andMe scientists discovered the target for 23ME-00610 through the Company's proprietary database of human genetic and health information. 23andMe has more than 15 million genotyped customers, roughly 80 percent of whom consent to participate in research. By analyzing de-identified, aggregate genetic and health data from consented research participants, 23andMe identified genetic variants of
Show less
Read more
Impact Snapshot
Event Time:
ME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ME alerts
High impacting 23andMe Holding Co. news events
Weekly update
A roundup of the hottest topics
ME
News
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseBusiness Wire
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- 23andMe announces CEO’s intention to pursue a potential take-privateGlobeNewswire
- Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
- 23andMe Holding Co. (NASDAQ: ME) had its price target lowered by analysts at Citigroup Inc. from $0.85 to $0.47. They now have a "neutral" rating on the stock.MarketBeat
ME
Sec Filings
- 4/19/24 - Form 4
- 4/18/24 - Form 8-K
- 4/17/24 - Form SC
- ME's page on the SEC website